In two unrelated cases, the Office of Research Integrity (ORI) has sanctioned a grad student and a pair of colleagues, one of whom plagiarized and the other allowed the intellectual theft to go unchecked.
We think the handling of these cases — both first noted briefly by The Chronicle of Higher Education — is worth noting.
Continue reading ORI roundup: Former SUNY grad student, two Kansas U researchers hit with sanctions
In the wake of the massive allegations of fraud by resveratrol researcher Dipak Das, other researchers in the field are clearly trying to distance themselves from the University of Connecticut scientist. Nir Barzilai told us yesterday, for example, that despite Das seemingly’ impressive publication record, “Rome was not built on Dr. Das.”
Harvard’s David Sinclair went further, telling The New York Times that he didn’t know who Das was: Continue reading So how peripheral was Dipak Das’ resveratrol work, really?
Many Retraction Watch readers will now be familiar with the case of Dipak Das, the resveratrol researcher about whom the University of Connecticut issued a voluminous report yesterday — summary here — detailing 145 counts of data fabrication and falsification. This has been a fast-moving story, so we wanted to highlight a number of updates to our original post, and offer a few more.
First, we have confirmed with publisher Mary Ann Liebert this morning that Das has been relieved of his duties as co-editor in chief of Antioxidants & Redox Signaling. He had shared that post with Chandan Sen, and his name as been removed from the masthead of that journal. Here’s a statement from the publisher: Continue reading Resveratrol fraud case update: Dipak Das loses editor’s chair, lawyer issues statement refuting all charges
The University of Connecticut, in what clearly seems like an attempt to get ahead of damaging news, has announced an “extensive” investigation into research misconduct involving one of its scientists, Dipak K. Das.
According to a press release, the university has notified 11 journals that published Das’ work about the alleged fraud. One area of interest for Das, a government-funded professor of surgery and director of the Cardiovascular Research Center, has been resveratrol, a substance in red wine that has allegedly been linked to improved cardiac health.
The university touted some of his early efforts in this field.
[Please also see our update posted Thursday.]
Here’s what the release has to say: Continue reading UConn resveratrol researcher Dipak Das fingered in sweeping misconduct case
The journal Cancer has issued an Expression of Concern about two lung cancer screening papers long dogged by doubt.
Last April, The Cancer Letter and The New York Times jointly published an investigation into the International Early Lung Cancer Action Program (I-ELCAP) run by Claudia Henschke and David Yankelevitz. Other researchers had already criticized the design and conclusions of that trial, but as the investigation noted, an October 2008 review of the study found that the researchers couldn’t find 90 percent of the subjects’ consent forms, an ethical no-no that jeopardizes as many as 135 papers.
Two papers published in Cancer, in 2000 and 2001, are among those studies, according to the notice (links added), which credits the Times and The Cancer Letter and notes that the journal has referred the case to Federal investigators: Continue reading Cancer issues expression of concern about two Henschke I-ELCAP lung cancer screening papers
The authors of a study in Urology that was at the center of two 2009 lawsuits brought by a company that funded the work have retracted the paper.
The idea behind the research — by Robert Getzenberg and colleagues at Johns Hopkins — was to find an alternative to the prostate specific antigen (PSA) test, which many urologists recommend, but which many groups — including the US Preventive Services Task Force — find wanting. The work gave rise to a company, Onconome, Science reported in a 2009 story about the lawsuits: Continue reading Hopkins scientists retract prostate cancer screening study at center of 2009 lawsuits
The January 2012 issue of Biosystems Engineering has a commendably thorough retraction notice regarding a case of plagiarism in its pages.
The notice, regarding the article “Advanced techniques for Weed and crop identification for site specific Weed management,” by Karan Singh, K.N. Agrawal, and Ganesh C. Bora, of North Dakota State University, speaks for itself: Continue reading Plagiarism kills weed paper
More than 14 months after Blood issued a notice of concern about a paper by a Harvard stem cell scientist and her former post-doc, the journal has retracted the article.
Here’s the notice for the paper, “Osteolineage niche cells initiate hematopoietic stem cell mobilization,” by Shane Mayack and Amy Wagers: Continue reading Blood retracts stem cell paper from Amy Wagers’ Harvard lab after 14 months of concern
Just days after the retraction of a paper in Science that had claimed a link between chronic fatigue syndrome (CFS) and the virus XMRV, the authors of a similar paper in the Proceedings of the National Academy of Sciences (PNAS) have retracted theirs.
The PNAS paper, “Detection of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors,” was published online on August 23, 2010 by Shyh-Ching Lo, Harvey Alter, and colleagues. Here’s the notice, which PNAS says will be available on its site sometime this week: Continue reading Another shoe drops as authors retract PNAS chronic fatigue syndrome-virus paper
The editors of Science have fully retracted a study they published in 2009 alleging a link between chronic fatigue syndrome (CFS) and the virus XMRV.
The notice begins with a nod to the reasons that the paper has already been partially retracted:
Science is fully retracting the Report “Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome” (1). Multiple laboratories, including those of the original authors (2), have failed to reliably detect xenotropic murine leukemia virus–related virus (XMRV) or other murine leukemia virus (MLV)–related viruses in chronic fatigue syndrome (CFS) patients. In addition, there is evidence of poor quality control in a number of specific experiments in the Report. Fig. 1, table S1, and fig. S2 have been retracted by the authors (3).
It also refers to evidence of image manipulation that was described by blogger Abbie Smith and then reported in the Chicago Tribune:
Continue reading Chronic fatigue syndrome-XMRV paper retracted by Science, completely this time
